Perinatal HIV-1 transmission: Recent advances and therapeutic interventions

AIDS, Supplement

Volumn 10, Issue 3, 1996, Pages

  Bryson, Yvonne J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Interventions; Perinatal HIV 1; Risk factors

Indexed keywords

CELL COUNT; CHORIOAMNIONITIS; CONFERENCE PAPER; HELPER CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAUTERINE INFECTION; MOTHER FETUS RELATIONSHIP; PRIMARY INFECTION; PRIORITY JOURNAL;

CLINICAL TRIALS; DISEASE TRANSMISSION, VERTICAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT, NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RISK FACTORS;

EID: 0029803478     PISSN: 13502840     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (69)

1. Connor EM, Sperling RS, Gelber R, et al.: Reduction of maternalinfant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994, 331:1173-1180.
2. Centers for Disease Control and Prevention: Recommendations of the US Public Health Service Task Force on the use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. MMWR 1994, 43 (RR-11):1-20.
3. European Collaborative Study: Risk factors for mother to child transmission of HIV infection. Lancet 1992, 339:1007-1012.
4. Peckham C, Gibb D: Mother to child transmission of the human immunodeficiency virus. N Engl J Med 1995, 333:298-302.
5. Halsey NA, Boulos R, Holt E, et al.: Transmission of HIV-1 infections from mothers to infants in Haiti. Impact on childhood mortality and malnutrition. The CDS/JHU AIDS Project Team. JAMA 1990, 264:2088-2092.
6. Centers for Disease Control and Prevention: Heterosexually acquired AIDS: United States, 1993. MMWR 1993, 43:155-160.
7. Matheson P, Thomas PA, Lambert G, et al.: Perinatal transmission of human immunodeficiency virus type 1 and heterosexual behavior during pregnancy. Third International Conference on Retroviruses and Opportunistic Infections. Washington, DC, January 1996 [abstract 28].
8. Bryson YJ, Luzuriaga K, Sullivan JL, Wara DW: Proposed definitions for in utero versus intrapartum transmission of HIV-1 [letter]. N Engl J Med 1992, 327:1246-1247.
9. Soeiro R, Rubinstein A, Rashbaum WK, et al.: Materno-fetal transmission of AIDS: frequency of HIV-1 nucleic acid sequences in human fetal DNA. J Infect Dis 1992, 166:699-703.
10. Lewis SH, Reynolds KC, Fox HE, et al.: HIV-1 in trophoblastic and villous Hofbauer cells, and hematological precursors in 8 week old fetuses. Lancet 1990, 335:565-568.
11. Langston C, Lewis DE, Hammill HA, et al.: Excess intrauterine fetal demise associated with maternal human immunodeficiency virus infection. J Infect Dis 1995, 172:1451-1460.
12. Dunn DT, Brandt CD, Krivine A, et al.: The sensitivity of HIV-1 DNA PCR in the neonatal period and the relative contributions of intrauterine and intrapartum transmission. AIDS 1995, 9:F7-F11.
13. Ehrnst A, Lindgren S, Dictor M, et al.: HIV in pregnant women and lheir offspring: evidence for late transmission [see comments]. Lancet 1991, 338:203-207.
14. Krivine A, Fintion G, Cao L, et al.: HIV replication during the first weeks of life. Lancet 1992, 339:1187-1189.
15. Dickover R, Kwok S, Wei L, Christopherson C, Bryson YJ: HIV RNA peak during primary viremia is a major determinant of clinical course in perinatally infected infants. Third International Conference on Retroviruses and Opportunistic Infections. Washington, DC, January-February 1996 [abstract 217].
16. Boyer PJ, Dillon M, Navaie M, et al.: Factors predictive of maternal-felal transmission of HIV-1. Preliminary analysis of zidovudine given during pregnancy and/or delivery. JAMA 1994, 271:1925-1930.
17. Goedert JJ, Duliege AM, Amos CI, Felton S, Biggar RJ: High risk of HIV-1 infection for first-born twins.The International Registry of HIV-Exposed Twins. Lancet 1991, 338:1471-1475.
18. Luzuriaga K, McQuilken P, Alimenti A, Somasundaran M, Hesselton R, Sullivan JL: Early viremia and immune responses in vertical human immunodeficiency virus type 1 infection. J Infect Dis 1993, 176:1008-1013.
19. Landesman SH, Kalish L, Burns DN, et al.: Obstetrical factors and the transmission of HIV type 1 from mother to child - WITS. N Engl J Med 1996, 334:1617-1623.
20. Nielsen K, Boyer P, Dillon M, et al.: Presence of human immunodeficiency virus (HIV) type 1 and HIV-1-specific antibodies in cervicovaginal secretions of infected mothers and in the gastric aspirates of their infants. J Infect Dis 1996, 173:1001-1004.
21. Stiehm ER, Vink P: Transmission of human immunodeficiency virus infection by breast feeding. J Pediatr 1991, 118:410-410.
22. Dunn DT, Newell ML, Ades AE, Peckham CS: Risk of human immunodeficiency virus type 1 transmission through breastfeeding. Lancet 1992, 340:585-588.
23. Fenyö EM: The role of the humoral immune response in HIV infection. AIDS 1996, 10 (suppl 1):S97-S106.
24. Centers for Disease Control: 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992, 41 (RR-17):1-19.
25. Walker BD, Plata F: Cytotoxic T lymphocytes against HIV. AIDS 1990, 4:177-184.
26. Bollinger RC, Egan MA, Chun TW: Cellular immune responses to HIV-1 in progressive and non-progressive infections. AIDS 1996, 10 (suppl 1):S85-S96.
27. Albert J, Abrahamsson B, Nagy K, et al.: Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. AIDS 1990, 4:107-112.
28. Panteleo C, Menzo S, Vaccarezza M, et al.: Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med 1995, 332:209-216.
29. Cao Y, Qin L, Zhang L, Safat J, Ho DD: Virological and immunologic characterization of long-term survivors of HIV-1. N Engl J Med 1995, 332:201-208.
30. Bryson YJ, Lehman D, Garratty E, Dickover R, Plaeger-Marshall S, O'Rourke S: The role of maternal autologous neutralizing antibody in prevention of maternal fetal HIV-1 transmission. J Cell Biochem 1993, (suppl 17E):95.
31. Husson RN, Lan Y, Kojima E, Venzon D, Mitsuya H, McIntosh K: Vertical transmission of human immunodeficiency virus type 1: autologous neutralizing antibody, virus load, and virus phenotype. J Pediatr 1995, 126:865-871.
32. Kliks SC, Wara DW, Landers DV, Levy JA: Features of HIV-1 that could influence maternal-child transmission. JAMA 1994, 272:467-474.
33. Scarlatti G, Albert J, Rossi P, et al.: Mother-to-child transmission of human immunodeficiency virus type 1: correlation with neutralizing antibodies against primary isolates. J Infect Dis 1993, 168:207-210.
34. Dickover RE, Garratty EM, Herman SA, et al.: Identification of levels of maternal HIV-1 RNA associated with risk of perinatal transmission: effect of maternal zidovudine treatment on viral load. JAMA 1996, 275:599-605.
35. Scarlatti G, Hodara V, Rossi P, et al.: Transmission of human immunodeficiency virus type 1 (HIV-1) from mother to child correlates with viral phenotype. Virology 1993, 197:624-629.
36. Wolinsky SM, Wike CM, Korber BT, et al.: Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants. Science 1992, 255:1134-1137.
37. Scarlatti G, Leitner T, Halapi E, et al.: Comparison of variable region 3 sequences of HIV type 1 from infected children with RNA and DNA sequences of the virus populations of their mothers. Proc Natl Acad Sci USA 1993, 90:1721-1725.
38. Zhu T, Mo H, Wang N, et al.: Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 1993, 261:1179-1181.
39. von Seidlein L, Garratty E, Dickover R, Bryson YJ: Lack of correlation of virus phenotype (synctia inducing) with onset and progression of disease in vertically HIV-1 infected infants. 1994 Keystone Symposium: Prevention and Treatment of AIDS. Hilton Head, SC, January 1994.
40. Spencer TL, Danker OM, Spector SA: Clinical significance of HIV-1 phenotype in infected children. J Infect Dis 1994, 169:491-495.
41. von Seidlein L, Plaeger S, Garratty E, et al.: Primary HIV-1 infection during pregnancy associated with transmission of precipitous loss of CD4 cells in mother and infant. J Pediatr 1996 (in press).
42. Blanche S, Mayaux MJ, Rouzioux C, et al.: Relation of the course of HIV infection in children to the severity of the disease in their mothers at delivery. N Engl J Med 1994, 330:308-312.
43. Tovo PA, deMartino M, Gabiano C, et al.: AIDS appearance in children is associated with the velocity of disease progression in their mothers. J Infect Dis 1994, 170:1000-1002.
44. Derossi A, Giaguinto C, Lometto A: Replication and tropism of HIV-1 as predictors of disease outcome in infants with vertically acquired infection. J Pediatr 1993, 12:929-936.
45. Borkowsky W, Krasinski K, Cao Y, et al.: Correlation of perinatal transmission of human immunodeficiency virus type 1 with maternal viremia and lymphocyte phenotypes. J Pediatr 1994, 123:345-351.
46. Fang G, Burger H, Grimson R, et al.: Maternal plasma human immunodeficiency virus type 1 RNA level: a determinant and projected threshold for mother-to-child transmission. Proc Natl Acad Sci USA 1995, 92:12100-12104.
47. Koup R, Yunzhen C, Ho D, et al.: Lack of maternal viral threshold for vertical transmission of HIV-1. Third International Conference on Retroviruses and Opportunistic Infections. Washington, DC, January-February 1996 [abstract LB2].
48. Sperling R, Shapiro D, Coombs R, et al.: Maternal plasma HIV-1 RNA and the success of zidovudine (ZDV) in the prevention of mother-child transmission. Third International Conference on Retroviruses and Opportunistic Infections. Washington, DC, January-February 1996 [abstract LB1].
49. Burchett S, Kornegay J, Pitt J, et al.: Assessment of maternal plasma HIV viral load as a correlate of vertical transmission. Third International Conference on Retroviruses and Opportunistic Infections. Washington, DC, January-February 1996 [abstract LB3].
50. Piatak M Jr, Saag MS, Yang LC, et al.: High levels of HIV-1 in plasma during all stages of infection as determined by competitive PCR. Science 1993, 259:1749-1754.
51. O'Brien WA, Hartigan PM, Martin D, et al.: Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. N Engl J Med 1996, 334:426-431.
52. O'Sullivan MJ, Boyer PJ, Scott GB, et al.: The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with HIV and their infants: Phase I ACTG 082. ZDV Collaborative Working Group. Am J Gynecol 1992, 168:1519-1516.
53. Dickover R, Herman S, Saddiq K, Wafer D, Bryson YJ: Stability of HIV-1 RNA in whole blood stored at room temperature and effect of anticoagulant. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, October 1996 [abstract 123].
54. Clerici M, Giorgi JV, Chou CC, et al.: Cell-mediated immune response to human immunodeficiency virus (HIV) type 1 in seronegative homosexual men with recent sexual exposure to HIV-1. J Infect Dis 1992, 165:1012-1019.
55. Rowland-Jones S, Nixon DF, Aldhous MC, et al.: HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant. Lancet 1993, 341:860-861.
56. Bakshi SS, Tetali S, Abrams EJ, Paul MO, Pahwa SG: Repeatedly positive human immunodeficiency virus type 1 DNA polymerase chain reaction in human immunodeficiency virus-exposed seroreverting infants. Pediatr Infect Dis J 1995, 14:658-662.
57. Bryson YJ, Wei L, Dickover R, Diagne A, Pang C, Chen ISY: Clearance of HIV infection in a vertically infected infant. N Engl J Med 1994, 332:833-838.
58. Newell M, Dunn D, De Maria A, et al.: Detection of virus in vertically exposed HIV-antibody-negative children. Lancet 1996, 347:213-215.
59. Rogues P, Gras G, Parnet-Mathieu F, et al.: Clearance of HIV infection in 12 perinatally infected children: clinical, virological and immunological data. AIDS 1995, 9:F20-F26.
60. Dunn DT, Newell ML, Mayaux T, et al.: Mode of delivery and vertical transmission of HIV-1. A review of prospective studies. Perinatal AIDS Collaborative Transmission Studies. J Acquir Immune Defic Syndr 1994, 7:1064-1066.
61. Connor E, Sperling R, Shapiro D, Oleske J, Fowler MG, and Protocol 076 and 219 Study Groups: Long term effect of ZDV exposure among uninfected infants born to HIV-infected mothers in PACTG Protocol 076. 36th tnterscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, October 1996 [abstract 111].
62. Fiscus SA, Adimora AA, Schoenbach VJ, et al.: Perinatal HIV infection and the effect of zidovudine therapy on transmission in rural and urban counties. JAMA 1996, 275:1483-1488.
63. Wiznia A: Zidovudine use to reduce perinatal HIV type 1 transmission in an urban medical center. JAMA 1996, 275:1504-1506.
64. Matheson PB, Abrams EJ, Thomas PA, et al.: Efficacy of antenatal zidovudine in reducing perinatal transmission of human immunodeficiency virus type 1. J Infect Dis 1995, 172:353-358.
65. Melvin AJ, Frenkel LM, Cowles MK, et al.: An observational study of vertical transmission when the mother but not the infant received oral zidovudine. XI International Conference on AIDS. Vancouver, July 1996 [abstract TuB2128].
66. Collier AC, Coombs RW: Treatment of HIV infection with saquinavir, zidovudine and zalcitabine. N Engl J Med 1996, 334:1011-1017.
67. Gulick R, Mellors J, Havlis D: Potent and sustained antiretroviral activity of indinavir (IDV) in combination with zidovudine (ZDV) and lamivudine (3TC). Third International Conference on Retroviruses and Opportunistic Infections. Washington, DC, January-February 1996 [abstract LB7].
68. Biggar RJ, Miotti PG, Taha TE, et al.: Perinatal intervention trial in Africa: effect of a birth canal cleansing intervention to prevent HIV transmission. Lancet 1996, 347:1647-1650.
69. Lambert J, Mofenson L, Fletcher C, et al.: Pharmacokinetics and safety of hyperimmune HIV immunoglobulin (HIVIG) in pregnant HIV-infected women. J Infect Dis 1996 (in press).